Megestrol acetate versus aminoglutethimide for metastatic breast cancer.
In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared. 176 patients were included, and 150 received treatment greater than 8 weeks and are evaluable for treatment response. The two groups did not differ with regard to prognostic factors. Response rate for the AG and MA groups were 34% and 31% respectively, with duration of response of 13.1 and 13.0 months. Stable disease was obtained in 33% and 35% respectively. No difference was observed in survival. Side effects occurred more frequently in the AG group (42%) than in the MA group (18%).
Lundgren
S
S
Department of Medical Oncology and Radiotherapy, University of Bergen, Norway.
Gundersen
S
S
Klepp
R
R
Lønning
P E
PE
Lund
E
E
Kvinnsland
S
S
D000368:Aged; D000616:Aminoglutethimide / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008535:Megestrol / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D013629:Tamoxifen / Q000627:therapeutic use
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D000616:Aminoglutethimide; D008535:Megestrol